Sanofi (EPA: SAN; NASDAQ: SNY), a leading French pharmaceutical company, has entered into a significant licensing agreement with US biotechnology firm RadioMedix Inc. and French company Orano Med, securing global rights to a radioligand therapy (RLT). The agreement centers on AlphaMexi (212Pb-DOTAMTATE), a targeted alpha therapy (TAT) that utilizes a somatostatin receptor-targeting peptide complex radiolabeled with lead-212 (212Pb), acting as an in vivo generator of alpha particles. This therapy is currently undergoing late-stage trials for adult patients with unresectable or metastatic, progressive somatostatin-receptor expressing neuroendocrine tumors (NETs). The drug was originally discovered by Orano, a specialist biotech company focused on leveraging the therapeutic potential of lead-212 (212Pb), an alpha-emitting radioisotope against cancer cells.
As per the terms of the deal, Sanofi will make an upfront payment of EUR 100 million (USD 110 million) to Orano and RadioMedix, with a commitment to an additional EUR 220 million (USD 243 million) in sales-based milestones and future sales royalties. Sanofi will handle global commercialization efforts, while Orano/RadioMedix will manage manufacturing and supply responsibilities. – Flcube.com
